Regeneron Pharma Stock (US75886F1075): Analyst support keeps the shares in view - AD HOC NEWS
π Analyst consensus price target for Regeneron Pharma is set at $792.65 per share.
π MarketBeat counts 27 analysts covering the stock with a 'moderate buy' rating.
π Report published on June 15, 2026, noting shares trade well below the target price.
π Company focuses on specialty therapies and drug development in ophthalmology, immunology, and oncology.
π’ Regeneron is listed on Nasdaq under ticker REGN and is a member of the Nasdaq Composite.
π No fresh earnings release or corporate action drove this specific analyst update.
Bullish Signals
- Strong analyst consensus price target of $792.65 suggests significant upside potential from current trading levels.
- Moderate buy rating from 27 analysts indicates sustained institutional interest and confidence in the company's long-term prospects.
- Continued Wall Street support keeps Regeneron on investor watchlists even during quiet trading periods.
Risk Factors
- Stock currently trades well below the consensus price target, indicating a potential valuation gap that requires fresh operating evidence to close.
- No new fundamental catalysts such as earnings releases or corporate actions were included in the recent analyst coverage.
Full Analysis
Regeneron Pharma (REGN) is the subject of an analyst roundup published by Ad-hoc-News on June 15, 2026, highlighting continued Wall Street support for the biotechnology company. The report indicates that the consensus price target stands at approximately $792.65 per share, a figure significantly higher than the stock's recent trading levels.
MarketBeat data cited in the article shows that 27 analysts cover Regeneron Pharma with an aggregated rating of 'moderate buy.' This coverage suggests that while there is no immediate debate over the company's existence or relevance, the primary market discussion centers on the remaining upside potential relative to current valuations.
The article clarifies that this news represents a valuation and sentiment story rather than a reaction to new fundamental data like earnings releases or corporate actions. Regeneron, headquartered in Tarrytown, New York, operates primarily in prescription medicines, specialty biologics, and drug development with key revenue drivers in ophthalmology, immunology, and oncology.